Literature DB >> 8547428

Distribution of endothelin receptor subtypes in the rat kidney. Renal and haemodynamic effects of the mixed (A/B) endothelin receptor antagonist bosentan.

B Hocher1, P Rohmeiss, F Diekmann, R Zart, V Vogt, S Schiller, C Bauer, K Koppenhagen, A Distler, N Gretz.   

Abstract

The paracrine renal endothelin system has been implicated in acute and chronic kidney diseases. However, there are only few data about the expression of endothelin receptor subtypes and their impact on renal function in the normal rat kidney. Therefore, we analyzed the age-dependent expression of endothelin receptors (endothelin receptor A and B) using Scatchard analysis, in vitro and in vivo receptor autoradiography. Furthermore, we investigated the effects of the mixed (A/B) endothelin receptor antagonist bosentan on haemodynamic and renal function in conscious chronically instrumented rats. The renal endothelin receptor A and endothelin receptor B expression is age-dependent. The relative amount of endothelin receptor A significantly decreased with age, whereas the endothelin receptor B significantly increased with age. Compared to the other renal structures, a high endothelin receptor density (endothelin receptor B >> endothelin receptor A) was seen in the renal tubules and even more in the glomeruli. Bosentan blocks both the pressor and depressor response of endothelin. Blocking of both endothelin receptor subtypes using bosentan without application of endothelin, on the other hand, did not alter blood pressure, heart rate, renal blood flow, water excretion or glomerular filtration rate, but significantly decreased sodium excretion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8547428     DOI: 10.1515/cclm.1995.33.8.463

Source DB:  PubMed          Journal:  Eur J Clin Chem Clin Biochem        ISSN: 0939-4974


  7 in total

1.  Endothelin-induced inositol phosphate formation in rat kidney. Studies on receptor subtypes, G-proteins and regulation during ontogenesis.

Authors:  K Becker; W Erdbrügger; I Heinroth-Hoffmann; M C Michel; O E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

2.  Endothelin type A receptor inhibition normalises intrarenal hypoxia in rats used as a model of type 1 diabetes by improving oxygen delivery.

Authors:  Stephanie Franzén; Fredrik Palm
Journal:  Diabetologia       Date:  2015-07-15       Impact factor: 10.122

3.  Nitric oxide modulates renal vasoconstrictor effect of endothelin-1 in conscious lambs.

Authors:  Francine G Smith; Liesbeth van der Velde; Alp Sener
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

Review 4.  The mechanism of increased renal susceptibility to toxic substances in the elderly. Part I. The role of increased vasoconstriction.

Authors:  M Jerkić; S Vojvodić; J M López-Novoa
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

5.  The endothelin system in Morris hepatoma-7777: an endothelin receptor antagonist inhibits growth in vitro and in vivo.

Authors:  Thiemo Pfab; Gisela Stoltenburg-Didinger; Christoph Trautner; Michael Godes; Christian Bauer; Berthold Hocher
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

6.  Paracrine renal endothelin system in rats with liver cirrhosis.

Authors:  B Hocher; R Zart; F Diekmann; P Rohmeiss; A Distler; H H Neumayer; C Bauer; P Gross
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

7.  Role of endothelin receptor antagonist; bosentan in cisplatin-induced nephrotoxicity in ovariectomized estradiol treated rats.

Authors:  Alieh Zahedi; Mehdi Nematbakhsh; Maryam Moeini; Ardeshir Talebi
Journal:  J Nephropathol       Date:  2015-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.